Multidrug resistant and extended-spectrum beta-lactamase (ESBL) producing proteus mirabilis from tertiary hospitals in four states in Southwest Nigeria
Date
2015
Journal Title
Journal ISSN
Volume Title
Publisher
Nigeria Association of Pharmacists in Academia (NAPA)
Abstract
Background: Multidrug resistant (MDR) and extended-spectrum beta-lactamase (ESBL) producing Gram-negative bacteria pose great threat to antibiotic treatment of life threatening infections worldwide. Objectives: This study investigated the occurrence and distribution of MDR and ESBL producing Proteus mirabilis among clinical isolates collected from tertiary hospitals in four states in Southwest Nigeria. Materials and Methods: One hundred and eight (108) none-duplicated P. mirabilis collected from microbiology units of tertiary hospitals in four states in Southwest Nigeria namely; Oyo, Osun, Ogun and Lagos state, after authentication with standard bacteriological method, were subjected to antibiotic susceptibility test against ten selected antibiotics using disc-diffusion method. Presumptive production of ESBL was determined by double disc synergy test among isolates with MDR phenotype that showed resistance to any of the third generation cephalosporin antibiotics. Results: Of the 108 clinical isolates of P. mirabilis collected from Oyo (39.8%), Osun (25.9%), Ogun (21.3%) and Lagos (13%) states, 60 (55.6%) showed MDR phenotype. Among the 60 MDR isolates collected in Oyo (50%), Lagos (10%), Ogun (21.7%) and Osun (18.3%), 66.7%, 66.7%, 30.8% and 9.1% of the isolates produced ESBL, respectively. Conclusion: This study recorded the occurrence of ESBL and MDR P. mirabilis in all the four states but higher percentage of ESBL-production among MDR P. mirabilis in two of the states, Oyo and Lagos. Hence, there is need for adequate monitoring of antibiotic use to prevent increased rate of ESBL-positive MDR P. mirabilis in these states and others in the nearest future.
Description
Keywords
Extended-spectrum beta-lactamase, Multidrug resistant Proteus mirabilis, Phenotypic screening, Tertiary hospital
